|
Extreme hypofractıonated radiosurgery in recurrent inoperable High-Grade Ultra-Large gliomas
|
T. Berber   , I. Harmankaya , F. Aksaray , Y. Büyükpolat , F. Adatepe , B.D. Yilmaz , S.T. Dinçer , G. Coşgun , Ç. Numanoglu , M.N. Güven , M.E. Gül , C. Yildirim , A.A. Erken |
| Okmeydani Training and Research Hospital, Radiation Oncology Department, Istanbul, Turkey , tanjuberber@hotmail.com |
|
|
Abstract: (838 Views) |
Background: To elucidate the efficacy and toxicity of brain re-radiotherapy for recurrent large inoperable gliomas using radiosurgery. Materials and Methods: Between 2014 and 2018, extreme hypofractionated radiosurgery was performed using Accuray’s Cyberknife® system on 14 lesions (12 patients) grade 4 recurrence lesions of 6 patients with anaplastic astrocytoma and 6 patients with glioblastoma who had previously undergone surgery and cranial radiotherapy and had a local-regional recurrence. Six patients (8 lesions) were given a biologic effective dose (BED10) of 48 Gy and lower, and six patients were given a BED10 of 59.5 Gy and higher. The Response Assessment in Neuro-Oncology Criteria (RANO) were used for tumor response, and the Common Terminology for Adverse Events (CTCAE) was used for adverse effect assessment. The primary endpoint was determined as overall survival, and first treatment and salvage treatment time. Results: The median age of the patients was 43 years, and the median Karnofsky Performance Status (KPS) was 70. The median time from the first radiotherapy to death was 34 months. The median time from the previous radiotherapy was 29.5 months (R:17-40). The median survival was 10 months for those with recurrence before 29.5 months and 11 months for those with recurrence after 29.5 months. The median total tumor volume was 29.224 mL (~30 mL). One grade 4 toxicity was observed. Conclusion: Radiosurgery can be used effectively as salvage therapy in ultra-large inoperable gliomas. |
|
| Keywords: Re-irradiation, radiosurgery, high-grade glioma, salvage, hypofractionated, recurrent. |
|
|
Full-Text [PDF 1522 kb]
(363 Downloads)
|
|
Type of Study: Original Research |
Subject:
Radiation Biology
|
|
|
|
|
|
|
| References |
1. Ostrom QT, Gittleman H, Liao P, et al. (2017) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol, 19(5): v1-v88. [ DOI:10.1093/neuonc/nox158] [ PMID] [ ] 2. Stupp R, Mason WP, Van Den Bent MJ, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 352(10): 987-96. [ DOI:10.1056/NEJMoa043330] [ PMID] 3. Chen L, Guerrero-Cazares H, Ye X, et al. (2013) Increased subventricular zone radiation dose correlates with survival in glioblastoma patients after gross total resection. Int J Radiat Oncol Biol Phys, 86(4): 616-22. [ DOI:10.1016/j.ijrobp.2013.02.014] [ PMID] [ ] 4. Oppitz, U, Maessen, D, Zunterer, H, et al. (1999) 3D-recurrence-patterns of gliobastomas after CT-planned postoperative irradiation. Radiother Oncol, 53(1): 53-7. [ DOI:10.1016/S0167-8140(99)00117-6] 5. Stupp R, Hegi ME, Mason WP, et al. (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol, 10(5): 459-66. [ DOI:10.1016/S1470-2045(09)70025-7] 6. Diksin M, Smith SJ, Rahman R (2017) The molecular and phenotypic basis of the glioma invasive perivascular niche. Int J Mol Sci, 18(11): 2342. [ DOI:10.3390/ijms18112342] [ PMID] [ ] 7. Trone J-C, Vallard A, Sotton S, et al. (2020) Survival after hypofractionation in glioblastoma: a systematic review and meta-analysis. Radiation Oncology, 15: 1-10. [ DOI:10.1186/s13014-020-01584-6] [ PMID] [ ] 8. Bloch O, Han SJ, Cha S, et al. (2012) Impact of extent of resection for recurrent glioblastoma on overall survival. J Neurosurg Sci, 117(6): 1032-8. [ DOI:10.3171/2012.9.JNS12504] [ PMID] 9. Scoccianti S, Perna M, Olmetto E, et al. (2020) Local treatment for relapsing glioblastoma: A decision-making tree for choosing between reirradiation and second surgery. Critical Reviews in Oncology/Hematology, 2020: 103184. [ DOI:10.1016/j.critrevonc.2020.103184] [ PMID] 10. Combs SE, Widmer V, Thilmann C, et al. (2005) Stereotactic radiosurgery (SRS) treatment option for recurrent glioblastoma multiforme (GBM). Cancer, 104(10): 2168-73. [ DOI:10.1002/cncr.21429] [ PMID] 11. Reynaud T, Bertaut A, Farah W, et al. (2018) Hypofractionated stereotactic radiotherapy as a salvage therapy for recurrent high-grade gliomas: Single-center experience. Technol Cancer Res Treat, 17: 1533033818806498. [ DOI:10.1177/1533033818806498] [ PMID] [ ] 12. Eren G, Zorlu F, Yazici G, et al. (2021) Stereotactic radiosurgery and fractionated stereotactic radiosurgery in patients with recurrent glial tumors. Int J Hemato Oncol, 31(4): 255-63. 13. Gutin PH, Iwamoto FM, Beal K, et al. (2009) Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys, 75(1): 156-63. [ DOI:10.1016/j.ijrobp.2008.10.043] [ PMID] [ ] 14. Fogh SE, Andrews DW, Glass J, et al. (2010) Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol, 28(18): 3048. [ DOI:10.1200/JCO.2009.25.6941] [ PMID] [ ] 15. Tsien C, Pugh S, Dicker A, et al. (2019) Randomized phase II trial of re-irradiation and concurrent bevacizumab versus bevacizumab alone as treatment for recurrent glioblastoma (NRG Oncology/RTOG 1205): initial outcomes and rt plan quality report. Oral Scientific Session, 105(1): S78. [ DOI:10.1016/j.ijrobp.2019.06.539] 16. Pirzkall A, McKnight TR, Graves EE, et al. (2001) MR-spectroscopy guided target delineation for high-grade gliomas. Int J Radiat Oncol Biol Phys, 50(4): 915-28. [ DOI:10.1016/S0360-3016(01)01548-6] 17. Wen PY, Macdonald DR, Reardon DA, et al. (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol, 28(11): 1963-72. [ DOI:10.1200/JCO.2009.26.3541] [ PMID] 18. Atkinson TM, Ryan SJ, Bennett AV, et al. (2016) The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer, 24(8): 3669-76. [ DOI:10.1007/s00520-016-3297-9] [ PMID] [ ] 19. Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observations. Journal of the American statistical association. J American Statistical Association 53(282): 457-81. [ DOI:10.1080/01621459.1958.10501452] 20. Сох D (1972) Regression models and life-tables. Journal of the Royal Statistical Society. Series B, 34(2): 187-220. [ DOI:10.1111/j.2517-6161.1972.tb00899.x] 21. Shaw E, Scott C, Souhami L, et al. (2000) Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Physics, 47(2): 291-8. [ DOI:10.1016/S0360-3016(99)00507-6] 22. Dirks P, Bernstein M, Muller P, et al. (1993) The value of reoperation for recurrent glioblastoma. Canadian journal of surgery, 36(3): 271-5. 23. Oppenlander ME, Wolf AB, Snyder LA, et al. (2014) An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity. Journal of Neurosugery, 120(4): 846-53. [ DOI:10.3171/2013.12.JNS13184] [ PMID] 24. Scoccianti S, Francolini G, Carta GA, et al. (2018) Re-irradiation as salvage treatment in recurrent glioblastoma: a comprehensive literature review to provide practical answers to frequently asked questions. Crit Rev Oncol Hematol, 126: 80-91. [ DOI:10.1016/j.critrevonc.2018.03.024] [ PMID] 25. Clarke J, Neil E, Terziev R, et al. (2017) Multicenter, phase 1, dose escalation study of hypofractionated stereotactic radiation therapy with bevacizumab for recurrent glioblastoma and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys , 99(4): 797-804. [ DOI:10.1016/j.ijrobp.2017.06.2466] [ PMID] [ ] 26. Yaprak G, Isık N, Gemici C, et al. (2020) Stereotactic radiotherapy in recurrent glioblastoma: a valid salvage treatment option. Stereotact Funct Neurosurg, 98(3): 167-75. [ DOI:10.1159/000505706] [ PMID] 27. Yazici G, Cengiz M, Ozyigit G, et al. (2014) Hypofractionated stereotactic reirradiation for recurrent glioblastoma. J Neurooncol, 120(1): 117-23. [ DOI:10.1007/s11060-014-1524-0] [ PMID] 28. Kazmi F, Soon YY, Leong YH, et al. (2019) Re-irradiation for recurrent glioblastoma (GBM): a systematic review and meta-analysis. J Neurooncol, 142(1): 79-90. [ DOI:10.1007/s11060-018-03064-0] [ PMID] 29. De Wit M, De Bruin H, Eijkenboom W, et al. (2004) Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology, 63(3): 535-7. [ DOI:10.1212/01.WNL.0000133398.11870.9A] [ PMID] 30. Lederman, G, Wronski, M, Arbit, E, et al. (2000) Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Am J Clin Oncol, 23(2): 155-9. [ DOI:10.1097/00000421-200004000-00010] [ PMID] 31. Hudes RS, Corn BW, Werner-Wasik M, et al. (1999) A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys, 43(2): 293-8. [ DOI:10.1016/S0360-3016(98)00416-7] 32. Hasan S, Chen E, Lanciano R, et al. (2015) Salvage fractionated stereotactic radiotherapy with or without chemotherapy and immunotherapy for recurrent glioblastoma multiforme: a single institution experience. Radiation Oncology, 5: 106. [ DOI:10.3389/fonc.2015.00106] [ PMID] [ ] 33. Vordermark D, Kölbl O, Ruprecht K, et al. (2005) Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer, 5(1): 1-7. [ DOI:10.1186/1471-2407-5-55] [ PMID] [ ] 34. Voynov G, Kaufman S, Hong T, et al. (2002) Treatment of recurrent malignant gliomas with stereotactic intensity modulated radiation therapy. American J Clinical Oncology, 25(6): 606-11. [ DOI:10.1097/00000421-200212000-00017] [ PMID] 35. Shepherd SF, Laing RW, Cosgrove VP, et al. (1997) Hypofractionated stereotactic radiotherapy in the management of recurrent glioma. Int J Radiat Oncol Biol Phys, 37(2): 393-8. [ DOI:10.1016/S0360-3016(96)00455-5] 36. Ruben JD, Dally M, Bailey M, et al. (2006) Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Physics, 65(2): 499-508. [ DOI:10.1016/j.ijrobp.2005.12.002] [ PMID] 37. Blonigen BJ, Steinmetz RD, Levin L, et al. (2010) Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery. Int J Radiat Oncol Biol Physics, 77(4): 996-1001. [ DOI:10.1016/j.ijrobp.2009.06.006] [ PMID] 38. Hudes RS, Corn BW, Werner-Wasik M, et al. (1999) A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys, 43(2): 293-8. [ DOI:10.1016/S0360-3016(98)00416-7] 39. Hall WA, Djalilian HR, Sperduto PW, et al. (1995) Stereotactic radiosurgery for recurrent malignant gliomas. Journal of clinical oncology, 13(7): 1642-8. [ DOI:10.1200/JCO.1995.13.7.1642] [ PMID] 40. Pannullo SC, Fraser JF, Moliterno J, et al. (2011) Stereotactic radiosurgery: a meta-analysis of current therapeutic applications in neuro-oncologic disease. Journal of neuro-oncology, 103(1): 1-17. [ DOI:10.1007/s11060-010-0360-0] [ PMID] |
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Berber T, Harmankaya I, Aksaray F, Büyükpolat Y, Adatepe F, Yilmaz B, et al . Extreme hypofractıonated radiosurgery in recurrent inoperable High-Grade Ultra-Large gliomas. Int J Radiat Res 2022; 20 (3) :643-648 URL: http://ijrr.com/article-1-4357-en.html
|
